<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009876</url>
  </required_header>
  <id_info>
    <org_study_id>HM-RE-2017-01</org_study_id>
    <nct_id>NCT04009876</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer</brief_title>
  <official_title>Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy NALIRINOX (5-FU/LV + Oxaliplatin + Nal-IRI) Followed by Chemoradiotherapy in Patients With Rectal Cancer in a Watch-and-wait Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de investigación HM</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntax for Science, S.L</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de investigación HM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II
      clinical trial to determine the efficacy and clinical complete response rate in patients with
      rectal cancer and tumor preoperative evaluation after NAC (Neoadjuvant Chemotherapy) with
      NALIRINOX (5-FU [fluorouracil)/LV [Leucovorin calcium] + oxaliplatin + nal-IRI [Liposomal
      Irinotecan]) and chemoradiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cCR (clinical complete response) rate in LARC ( locally advanced rectal cancer ) patients treated with chemo - chemoradiation.</measure>
    <time_frame>expected 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that follow the &quot;watch-and-wait&quot; surveillance protocol</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
    <description>acute and late toxicity of neoadjuvant treatment (chemo and chemoradiotherapy) according to the Common Toxicity Criteria (CTC) for adverse events (AE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Locally Advanced Rectal Cancer (LARC)</condition>
  <arm_group>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and &quot;watch-and-wait&quot; surveillance protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nal-IRI</intervention_name>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>Surgical resection of the tumour</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Watch-and-wait</intervention_name>
    <description>No surgery approach</description>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/LV</intervention_name>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females, aged ≥ 18 years.

          -  Agree to participate and sign voluntary written ICF (Informed Consent Form) before any
             study specific procedure.

          -  Patients with confirmed histopathological diagnosis of rectal cancer.

          -  Patients with locally advanced rectal cancer T3-T4N0M0 or TxN+M0 and selected T2N0M0
             candidates to watch &amp; wait program.

          -  Patients considered for neoadjuvant treatment according to usual clinical practice may
             also be potential candidates.

          -  ECOG (Eastern Cooperative Oncology Grou)vperformance status 0 or 1.

          -  Patients who can receive radiotherapy and chemotherapy.

          -  No prior or concurrent malignant disease unless in complete remission for more than
             three years, except for adequately treated in situ carcinoma of the cervix, basal or
             squamous skin cell carcinoma or in situ transitional bladder cell carcinoma.

          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             before study entry. Both women and men must agree to use a highly effective
             contraceptive measure throughout the treatment period and for six months after
             discontinuation of treatment.

          -  Adequate hematologic function: hemoglobin ≥ 9g/dL; WBC (white blood cell count ) ≥
             4000/mm 3 ; neutrophils ≥ 1.5x10 9 /L; platelets ≥ 100x10 9 /L.

          -  Adequate hepatic function: total bilirubin ≤ 1.5xULN; ALT / AST (Alanine
             aminotransferase / Aspartate aminotransferase) ≤ 2.5xULN (Upper Limit of Normality)
             alkaline phosphatase ≤ 3xULN.

          -  Adequate renal function: creatinine ≤ 1xULN; creatinine clearance ≥ 60ml/min.

          -  No peripheral neuropathy (&lt; Grade 2)

          -  No known history of dihydropyrimidine dehydrogenase deficiency (DPD)

        Exclusion Criteria:

          -  Patients with ECOG performance status ≥ 2.

          -  Stage I (T1N0M0) or stage IV (TxNxM1) AJCC (American Joint Committee on Cancer) rectal
             cancer.

          -  Any illness that the investigator considers will substantially increase the risk if
             the patient participates in the study.

          -  Pregnant or breast-feeding woman.

          -  Chronically active hepatitis B or C virus infection.

          -  Active uncontrolled infection.

          -  History, within last year, or presence of unstable angina, myocardial infarction,
             symptomatic congestive heart failure or asymptomatic left ventricular ejection
             fraction &lt; 50% (assessed by multiple-gated acquisition scan or equivalent by
             ultrasound) or clinically significant valvular heart disease.

          -  Peripheral neuropathy (&gt; Grade 1)

          -  Known history of dihydropyrimidine dehydrogenase deficiency (DPD)

          -  Known or suspected reactions to any component of the study medication (5-FU,
             leucovorin, irinotecan or oxaliplatin) or to components of similar chemical or
             biologic composition.

          -  Any phycological, familiar, sociological or geographical condition potentially
             hampering compliance with the study protocol or follow-up schedule.

          -  Concurrent participation in any other clinical trial likely to interfere with the
             therapeutic schedule.

          -  Patients that had received any previous treatment for their rectal cancer (surgery,
             chemotherapy or radiotherapy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cubillo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Cubillo, MD</last_name>
    <phone>+34 917567800</phone>
    <email>secretaria@fundaciónhm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Sanchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Sanchinarro</city>
        <state>Madrid</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Muñoz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cesar Muñoz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pilar García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria del Carmen Riesco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria del Carmen Riesco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

